Login to Your Account



Search

Search results

Pharma: Clinic Roundup

• Asahi Kasei Pharma America Corp. , of Waltham, Mass., said it started an 800-patient Phase III trial of ART-123 (recombinant human thrombomodulin, sold as Recomodulin in Japan) in severe sepsis patients with coagulopathy. (BioWorld-T ...

BioWorld Today - Staff - 2012-11-01 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• A.P. Pharma Inc. , of Redwood City, Calif., reported additional data from a Phase III trial of APF530, for chemotherapy-induced nausea and vomiting. (BioWorld-Today-2012-07-02) ...

BioWorld Today - Staff - 2012-07-02 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Galleon Pharmaceuticals Inc. , of Horsham, Pa., said its drug candidate GAL-021 was safe and well tolerated in a Phase I trial in 30 healthy adults. The company is investigating GAL-021 for improving breathing in patients receiving opioids, w ...

BioWorld Today - Staff - 2012-05-08 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Cempra Inc. , of Chapel Hill, N.C., presented data at the American Thoracic Society International Conference (ATS 2013) in Philadelphia demonstrating the antibacterial and enhanced immunomodulatory activity of solithromycin vs. levofloxacin i ...

BioWorld Today - Staff - 2013-05-21 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Teva Pharmaceuticals Industries Ltd. , of Jerusalem, said data that demonstrates significant differences in biological and immunological effects between Copaxone (glatiramer acetate, GA) and a purported generic glatiramer acetate (GA), marketed in In ...

BioWorld Today - Staff - 2014-01-14 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Baxter International Inc. , of Deerfield, Ill., said it started dosing patients with malignant solid tumors in a Phase I study of a fully human recombinant anti-macrophage migration inhibitory factor (MIF) monoclonal antibody. (BioWo ...

BioWorld Today - Staff - 2012-09-06 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Pfizer Inc. , of New York, said a Phase IIIb withdrawal design study for Lyrica (pregabalin) in patients with inadequately treated painful diabetic peripheral neuropathy did not meet its primary endpoint, defined as the change in mean pain score ...

BioWorld Today - Staff - 2012-05-07 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• UCB SA , of Brussels, Belgium, reported post-hoc analyses of pivotal trials of Neupro (rotigotine transdermal system) in patients with restless legs syndrome (RLS)/Willis Ekbom disease, showing improvements with rotigotine vs. placebo in most of ...

BioWorld Today - Staff - 2012-04-26 00:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Avillion Group , of London, said it entered an exclusive collaborative development agreement with Pfizer Inc. , of New York, to conduct a Phase III trial of Bosulif (bosutinib). (BioWorld-Today-2014-01-10) ...

BioWorld Today - Staff - 2014-01-10 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Astrazeneca plc , of London, reported phase III data showing that the combination of saxagliptin/dapagliflozin, as a dual add-on therapy in adults with type 2 diabetes who were inadequately controlled on metformin, resulted in statistically significa ...

BioWorld Today - Staff - 2014-05-14 00:00 - 0 comments - 0 attachments